Martin Welschof
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis.
The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin one of Ireland’s leading academic institution with a core focus on immunology research. Opsona's lead product, a fully human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of animal models & recently was tested successfully in a phase 1 clinical trial in healthy volunteers. The Company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft Function(DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012.
The Company is supported by an international venture consortium including Novartis Venture Fund, Roche Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners, Inventages Venture Capital and Enterprise Ireland. Further information is available at http://www.opsona.com/.
